Skip to main content

Generic Forane Availability

Last updated on Sep 10, 2026.

Forane is a brand name of isoflurane, approved by the FDA in the following formulation:

FORANE (isoflurane - liquid; inhalation)
Manufacturer Approval date Strengths [RLD] [AN]
BAXTER HLTHCARE Approved Prior to Jan 1, 1982
  • 99.9% [RLD] [AN]

Has a generic version of Forane been approved?

Yes, the FDA has approved a generic version of Forane. However, FDA approval doesn't guarantee the generic will be available in pharmacies.

ISOFLURANE (isoflurane liquid; inhalation)
Manufacturer Approval date Strengths [AN]
PIRAMAL CRITICAL September 30, 1994
  • 99.9% [AN]
PIRAMAL PHARMA June 27, 1995
  • 99.9% [AN]
HALOCARBON PRODS October 20, 1999
  • 99.9% [AN]
SHANDONG November 4, 2025
  • 99.9% [AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Forane. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Generic Forane prices

The pricing data below reflects current availability in the marketplace and indicates that the medication is available for purchase.

DrugFormStrengthDrugs.com Price Guide
Isofluraneinhalation liquid100%from $22.25 for 100
Terrellinhalation liquid100%from $22.25 for 100

See all prices for: Isoflurane, Terrell

Generic Forane Marketing Start Dates

Marketing start dates are when each generic version first became available from each manufacturer.

Start Date Labeler NDC Number Form Price
October 20, 1999 Halocarbon Life Sciences, LLC 12164-012 Liquid 1, mL/mL
February 28, 2010 Piramal Critical Care, Inc. 66794-011 Liquid 1, mL/mL
October 7, 2011 Piramal Critical Care, Inc. 66794-017 Liquid 1, mL/mL
March 21, 2012 Piramal Critical Care Inc 66794-019 Liquid 1, mL/mL
November 13, 2013 Piramal Critical Care, Inc. 66794-020 Liquid 1, mL/mL
November 4, 2025 Shandong New Time Pharmaceutical Co., Ltd. 42677-326 Liquid 100, mL/100mL
November 4, 2025 Shandong New Time Pharmaceutical Co., Ltd. 42677-327 Liquid 250, mL/250mL
April 1, 2026 Mullan Pharmaceutical Inc. 83301-0071 Liquid 100, mL/100mL
April 1, 2026 Mullan Pharmaceutical Inc. 83301-0072 Liquid 250, mL/250mL

Related/similar drugs

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AN Solutions and powders for aerosolization. Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded AN. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded BN, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded AN if the bioequivalence standard is based upon in vitro methodology, if bioequivalence needs to be demonstrated by in vivo methodology then the drug products will be coded AB.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.